非小细胞肺癌患者免疫相关不良事件的管理
Management of Immune-Related Adverse Events in Patients With Non-Small Cell Lung Cancer.
作者信息
Burke Michael, Rashdan Sawsan
机构信息
Department of Internal Medicine, Division of Hematology and Oncology, University of Texas Southwestern Medical Center, Dallas, TX, United States.
出版信息
Front Oncol. 2021 Sep 30;11:720759. doi: 10.3389/fonc.2021.720759. eCollection 2021.
Abstract
With proven efficacy of the use of immunotherapy in almost all stages of NSCLC, immunotherapy toxicity has become a very important topic that requires immediate recognition and management. The diagnosis of toxicities associated with immunotherapy in lung cancer can be very challenging and often requires multidisciplinary effort. This mini review gives an overview of the diagnosis and management of immune-related adverse events that arise from using immunotherapy in NSCLC, as well as the potential biomarkers for its early identification and future directions.
摘要
鉴于免疫疗法在非小细胞肺癌（NSCLC）几乎所有阶段都已证实具有疗效，免疫疗法的毒性已成为一个非常重要的话题，需要立即识别和处理。肺癌中与免疫疗法相关的毒性诊断可能极具挑战性，通常需要多学科协作。本综述概述了在NSCLC中使用免疫疗法引发的免疫相关不良事件的诊断和管理，以及其早期识别的潜在生物标志物和未来方向。
相似文献
1
Management of Immune-Related Adverse Events in Patients With Non-Small Cell Lung Cancer.非小细胞肺癌患者免疫相关不良事件的管理
Front Oncol. 2021 Sep 30;11:720759. doi: 10.3389/fonc.2021.720759. eCollection 2021.
2
Immune checkpoint blockade as a potential therapeutic target in non-small cell lung cancer.免疫检查点阻断作为非小细胞肺癌的潜在治疗靶点。
Expert Opin Biol Ther. 2016 Oct;16(10):1209-23. doi: 10.1080/14712598.2016.1214265. Epub 2016 Aug 5.
3
Optimal management of immune-related adverse events resulting from treatment with immune checkpoint inhibitors: a review and update.免疫检查点抑制剂治疗相关免疫相关不良事件的最佳管理：综述与更新。
Int J Clin Oncol. 2018 Jun;23(3):410-420. doi: 10.1007/s10147-018-1259-6. Epub 2018 Mar 7.
4
PD-1/PD-L1 Blockade Therapy in Advanced Non-Small-Cell Lung Cancer: Current Status and Future Directions.PD-1/PD-L1 阻断疗法在晚期非小细胞肺癌中的应用：现状与未来方向。
Oncologist. 2019 Feb;24(Suppl 1):S31-S41. doi: 10.1634/theoncologist.2019-IO-S1-s05.
5
Immune-Related Pneumonitis After Chemoradiotherapy and Subsequent Immune Checkpoint Blockade in Unresectable Stage III Non-Small-Cell Lung Cancer.不可切除 III 期非小细胞肺癌放化疗后免疫相关肺炎及随后的免疫检查点阻断。
Clin Lung Cancer. 2020 Sep;21(5):e435-e444. doi: 10.1016/j.cllc.2020.02.025. Epub 2020 Mar 9.
6
Immune Checkpoint Immunotherapy for Non-Small Cell Lung Cancer: Benefits and Pulmonary Toxicities.免疫检查点抑制剂治疗非小细胞肺癌：获益与肺部毒性。
Chest. 2018 Dec;154(6):1416-1423. doi: 10.1016/j.chest.2018.08.1048. Epub 2018 Sep 4.
7
Immune checkpoint inhibitors in advanced non-small cell lung cancer.免疫检查点抑制剂在晚期非小细胞肺癌中的应用。
Cancer. 2018 Jan 15;124(2):248-261. doi: 10.1002/cncr.31105. Epub 2017 Dec 6.
8
A multidisciplinary approach to toxicity management of modern immune checkpoint inhibitors in cancer therapy.癌症治疗中现代免疫检查点抑制剂毒性管理的多学科方法。
Melanoma Res. 2016 Oct;26(5):469-80. doi: 10.1097/CMR.0000000000000273.
9
The landscape of immune checkpoint inhibitor therapy in advanced lung cancer.晚期肺癌中免疫检查点抑制剂治疗的概况
BMC Cancer. 2021 Aug 28;21(1):968. doi: 10.1186/s12885-021-08662-2.
10
Circulating Biomarkers of Response and Toxicity of Immunotherapy in Advanced Non-Small Cell Lung Cancer (NSCLC): A Comprehensive Review.晚期非小细胞肺癌（NSCLC）免疫治疗反应和毒性的循环生物标志物：综述
Cancers (Basel). 2021 Apr 9;13(8):1794. doi: 10.3390/cancers13081794.
引用本文的文献
1
Advances in Multimodal Imaging Techniques for Evaluating and Predicting the Efficacy of Immunotherapy for NSCLC.用于评估和预测非小细胞肺癌免疫治疗疗效的多模态成像技术进展
Cancer Manag Res. 2025 Jun 7;17:1073-1086. doi: 10.2147/CMAR.S522136. eCollection 2025.
2
Exosomal LncRNAs and CircRNAs in lung cancer: Emerging regulators and potential therapeutic targets.肺癌中的外泌体长链非编码RNA和环状RNA：新兴的调控因子和潜在的治疗靶点
Noncoding RNA Res. 2024 Jun 12;9(4):1069-1079. doi: 10.1016/j.ncrna.2024.06.010. eCollection 2024 Dec.
3
Anti-PD-1 sintilimab-induced bilateral optic neuropathy in non-small cell lung cancer: A case report and literature review.抗程序性死亡蛋白1（PD-1）抗体信迪利单抗诱发非小细胞肺癌患者双侧视神经病变：一例报告及文献复习
Front Oncol. 2022 Aug 9;12:931074. doi: 10.3389/fonc.2022.931074. eCollection 2022.
4
Liquid biopsy in lung cancer: significance in diagnostics, prediction, and treatment monitoring.液体活检在肺癌中的应用：在诊断、预测和治疗监测中的意义。
Mol Cancer. 2022 Jan 20;21(1):25. doi: 10.1186/s12943-022-01505-z.
本文引用的文献
1
Immunotherapy-Mediated Thyroid Dysfunction: Genetic Risk and Impact on Outcomes with PD-1 Blockade in Non-Small Cell Lung Cancer.免疫治疗相关甲状腺功能障碍：非小细胞肺癌中 PD-1 阻断的遗传风险和对结局的影响。
Clin Cancer Res. 2021 Sep 15;27(18):5131-5140. doi: 10.1158/1078-0432.CCR-21-0921. Epub 2021 Jul 8.
2
Immune-Related Adverse Events Predict the Efficacy of Immune Checkpoint Inhibitors in Lung Cancer Patients: A Meta-Analysis.免疫相关不良事件可预测免疫检查点抑制剂对肺癌患者的疗效：一项荟萃分析
Front Oncol. 2021 Mar 1;11:631949. doi: 10.3389/fonc.2021.631949. eCollection 2021.
3
First-Line Nivolumab Plus Ipilimumab Versus Chemotherapy in Advanced NSCLC With 1% or Greater Tumor PD-L1 Expression: Patient-Reported Outcomes From CheckMate 227 Part 1.一线纳武利尤单抗联合伊匹木单抗对比化疗用于 PD-L1 肿瘤表达比例≥1%的晚期 NSCLC：CheckMate 227 研究的患者报告结局 1 部分
J Thorac Oncol. 2021 Apr;16(4):665-676. doi: 10.1016/j.jtho.2020.12.019. Epub 2021 Jan 21.
4
Management of endocrine immune-related adverse events of immune checkpoint inhibitors: an updated review.免疫检查点抑制剂内分泌免疫相关不良事件的管理：最新综述
Endocr Connect. 2020 Oct;9(10):R207-R228. doi: 10.1530/EC-20-0342.
5
The mechanism and risk factors for immune checkpoint inhibitor pneumonitis in non-small cell lung cancer patients.非小细胞肺癌患者免疫检查点抑制剂相关性肺炎的机制和危险因素。
Cancer Biol Med. 2020 Aug 15;17(3):599-611. doi: 10.20892/j.issn.2095-3941.2020.0102.
6
A Potential Mechanism of Anticancer Immune Response Coincident With Immune-related Adverse Events in Patients With Renal Cell Carcinoma.肾细胞癌患者抗癌免疫反应与免疫相关不良事件同时发生的潜在机制
Anticancer Res. 2020 Sep;40(9):4875-4883. doi: 10.21873/anticanres.14490.
7
Endocrine Adverse Events of Nivolumab in Non-Small Cell Lung Cancer Patients-Literature Review.纳武单抗治疗非小细胞肺癌患者的内分泌不良事件——文献综述
Cancers (Basel). 2020 Aug 17;12(8):2314. doi: 10.3390/cancers12082314.
8
Immune-Related Pneumonitis After Chemoradiotherapy and Subsequent Immune Checkpoint Blockade in Unresectable Stage III Non-Small-Cell Lung Cancer.不可切除 III 期非小细胞肺癌放化疗后免疫相关肺炎及随后的免疫检查点阻断。
Clin Lung Cancer. 2020 Sep;21(5):e435-e444. doi: 10.1016/j.cllc.2020.02.025. Epub 2020 Mar 9.
9
Efficacy and Toxicity of Immune -Checkpoint Inhibitors in Patients With Preexisting Autoimmune Disorders.免疫检查点抑制剂在已有自身免疫性疾病患者中的疗效与毒性
Front Med (Lausanne). 2020 May 7;7:137. doi: 10.3389/fmed.2020.00137. eCollection 2020.
10
Immune checkpoint inhibitor-related colitis assessment and prognosis: can IBD scoring point the way?免疫检查点抑制剂相关结肠炎的评估和预后：IBD 评分能指明方向吗？
Br J Cancer. 2020 Jul;123(2):207-215. doi: 10.1038/s41416-020-0882-y. Epub 2020 May 18.
Zotero 插件